News

COVID-19.info

Popularization of research advances on COVID-19

Website developed by 100pour100 MEDECINE

Vaccines

What is the effectiveness of a single dose of the Pfizer-BioNTech vaccine?

The mRNA Pfizer-BioNTech vaccine was the first vaccine against SARS- CoV- 2 to be made available. Two doses of the vaccine confer 95% protection against the original Wuhan strain of the virus. But this effectiveness is lessened if both vaccines are not given, and depends on the nature of variants. The UK took the decision to vaccinate […]

Read more...

Is the Pfizer-BioNTech vaccine effective in the over-80s?

The massive vaccination of populations is one of our greatest hopes for ending the COVID-19 pandemic. Vaccines based on the original Wuhan strain of the virus enable the production of antibodies directed against SARS-CoV-2. The Pfizer-BioNTech and Moderna mRNA vaccines give excellent protection against COVID-19 when 2 injections are administered. However, little data exists concerning […]

Read more...

Improving the cellular response from mRNA vaccines

The emergence of SARS-CoV-2 variants with higher transmissibility and with some capacity to escape neutralising antibodies has called into question the efficacy of currently used vaccines. In addition, the numerous strains of coronavirus already identified in bats suggests a real possibility of future epidemics. The development of vaccines capable of conferring protection against all these […]

Read more...
Read more...

The mRNA vaccines present no danger for pregnant women

The first vaccines against SARS-CoV-2 to receive authorisation were both mRNA vaccines: Pfizer-BioNTech and Moderna. However, the first clinical studies carried out on these vaccines did not include pregnant women. Pregnancy does increase the risk of developing a severe form of COVID-19 and infection may also have adverse effects on gestation and the foetus. Researchers […]

Read more...

A new study on the vaccination of people who have already been infected

Neutralising antibodies are an essential component of the immune response against SARS-CoV-2. In individuals who have not yet been infected, the 2 mRNA vaccines (Pfizer-BioNTech and Moderna), built using the original Wuhan strain of the virus, trigger the production of neutralising antibodies and have shown more than 94% efficacy. But recently, numerous SARS-CoV-2 variants have […]

Read more...

Should people who have already been infected be vaccinated?

More than a year after the start of the COVID-19 pandemic, it remains difficult to control the virus’ spread despite the development of vaccines. Progress has been slowed due to the emergence of variants that are more transmissible and more resistant to antibodies. In this combat, it is important to know whether long-term immune protection […]

Read more...

The effectiveness of the Janssen vaccine

Several vaccinations are now on the market and they remain our best weapon to combat the spread of SARS-CoV-2. But the emergence of new variants, in particular the Alpha (⍺ or UK), the Beta (β or South African), the Epsilon (𝛇 or Californian), and the Gamma (ɣ or Brazilian) variants, may reduce the effectiveness of […]

Read more...

Is the Pfizer-BioNTech vaccine one step ahead?

As SARS-CoV-2 continues to spread, new variants carrying mutations are emerging. These mutations, especially in the spike (S) surface protein, may lead to increased virus transmissibility. They can also engender resistance to current vaccines, such as the Pfizer-BioNTech mRNA vaccine, which was the first vaccine to be authorised for use. Some variants that have emerged […]

Read more...

The complexities of the mRNA vaccines antibody response

Immune response following infection by SARS-CoV-2 has now been well documented. However, responses following vaccination, in particular with mRNA vaccines (Pfizer-BioNTech and Moderna) has been less well studied, since these vaccines have only been available since the end of 2020. The principal target of the antibodies is the RBD (Receptor Binding Domain) of the spike […]

Read more...
error: Content is protected !!